*Press Note*

| BSE: 500257 | NSE: LUPIN | REUTERS: LUPIN.BO | BLOOMBERG: LPCIN |
|---|---|---|---|

# U.S. FDA completes inspection of Lupin's Vizag API facility

**Mumbai, January 18, 2020**: Pharma major Lupin Limited (Lupin) today announced the completion of an inspection carried out by the United States Food and Drug Administration (U.S. FDA) at its Vizag API manufacturing facility. The inspection was carried out between January 13, 2020 and January 17, 2020.

The inspection for the API facility at Vizag closed with five 483 observations.

Commenting on the outcome of the inspection, **Nilesh Gupta, Managing Director, Lupin** said, "We are fully committed to adherence with CGMP regulations and uphold high quality standards across all our manufacturing sites. We are confident of addressing the observations to the U.S. FDA's satisfaction".

**About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8$^{th}$ largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3$^{rd}$ largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3$^{rd}$ largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); and 6$^{th}$ largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2019).

For the financial year ended March 31, 2019, Lupin's Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on LinkedIn and Facebook at https://www.linkedin.com/company/lupinglobal/ and https://www.facebook.com/Lupin-Global respectively.

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055

**For further information or queries please contact:**

**Arvind Bothra**
Head – Investor Relations and M&A / Corporate Communications
Email: arvindbothra@lupin.com |
Ph: +91-22-66408237